Algerian Radio
The Saidal Group and Novo Nordisk announced on Monday the release of the first next-generation insulin pens on the Algerian market—specifically "Tresiba"—resulting from a strategic partnership between the two laboratories, according to a statement from the public group.
The launch ceremony took place at the Novo Nordisk headquarters in Boufarik, in the Wilaya of Blida. In attendance were Nabila Benygzer, Chairperson and CEO of the Saidal Group, Hamza Benharkat, General Manager of Novo Nordisk Algeria, as well as senior executives from both groups and representatives of national and local authorities.
Given the significance of diabetes as a major public health challenge, the two partners worked in close collaboration to accelerate the project's realization. Discussions began in September, followed by the signing of a memorandum of understanding and a contract in October, culminating today in the effective availability of the product on the national market, the statement specified.
Full-process production has already been initiated at the Constantine site, with the objective of achieving full local manufacturing of the product in the short term. The agreement also provides for the gradual integration of innovative therapeutic solutions developed by Novo Nordisk, ensuring Algerian patients have access to cutting-edge treatments.
This initiative represents a major step forward in improving care for diabetic patients. It aligns with the strategy to strengthen national production and consolidate the country's health security, in accordance with the directives of the President of the Republic, Abdelmadjid Tebboune, the source highlighted.
